» Articles » PMID: 17042504

N-terminal Fragments of Tau Inhibit Full-length Tau Polymerization in Vitro

Overview
Journal Biochemistry
Specialty Biochemistry
Date 2006 Oct 18
PMID 17042504
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

The polymerization of the microtubule-associated protein, tau, into insoluble filaments is a common thread in Alzheimer's disease and in a variety of frontotemporal dementias. The conformational change required for tau to transition from an extended monomeric state to a filamentous state with a high beta-sheet content involves the extreme N-terminus coming into contact with distal portions of the molecule; however, these exact interactions are incompletely understood. Here we report that a construct representing amino acids 1-196 (Tau196), which itself does not polymerize, inhibits polymerization of full-length tau (hTau40) in vitro. In addition, we trace the inhibitory effect of Tau196 to amino acids 18-42 of the construct. We also provide evidence that the N-terminal tau fragments require a specific C-terminal region of tau (residues 392-421) to exert their inhibitory effect. The fragments are most effective at inhibiting polymerization when present during the initial 5 min; they remain in the soluble fraction of the polymerization reaction, and they increase the amount of soluble hTau40. The fragments also reduce the number and average length of filaments that are formed. Taken together, these results suggest that the N-terminal tau fragments inhibit hTau40 polymerization by interacting with a specific C-terminal sequence, thereby stabilizing a soluble conformation of tau.

Citing Articles

Vulnerability of the entorhinal cortex II to neurodegeneration in Alzheimer's disease.

Reyes-Pablo A, Luna-Viramontes N, Montiel-Sosa J, Ontiveros-Torres M, Garces-Ramirez L, de la Cruz-Lopez F Brain Commun. 2025; 7(2):fcaf091.

PMID: 40078869 PMC: 11897590. DOI: 10.1093/braincomms/fcaf091.


Inducing aggresome and stable tau aggregation in Neuro2a cells with an optogenetic tool.

Sakuragi S, Uchida T, Kato N, Zhao B, Takahashi T, Hattori A Biophys Physicobiol. 2025; 21(4):e210023.

PMID: 39963597 PMC: 11832247. DOI: 10.2142/biophysico.bppb-v21.0023.


Proteolysis of tau by granzyme A in tauopathies generates fragments that are aggregation prone.

Quinn J, Fisher K, Corbett N, Warwood S, Knight D, Kellett K Biochem J. 2024; 481(18):1255-1274.

PMID: 39248243 PMC: 11555691. DOI: 10.1042/BCJ20240007.


The Enigma of Tau Protein Aggregation: Mechanistic Insights and Future Challenges.

Zheng H, Sun H, Cai Q, Tai H Int J Mol Sci. 2024; 25(9).

PMID: 38732197 PMC: 11084794. DOI: 10.3390/ijms25094969.


Exploring the significance of caspase-cleaved tau in tauopathies and as a complementary pathology to phospho-tau in Alzheimer's disease: implications for biomarker development and therapeutic targeting.

Rizzi L, Grinberg L Acta Neuropathol Commun. 2024; 12(1):36.

PMID: 38419122 PMC: 10900669. DOI: 10.1186/s40478-024-01744-9.